Stay updated with breaking news from Context Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6...
Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 44,900 shares, a growth of 14.5% from the September 30th total of 39,200 shares. Based on an average daily trading volume, of 36,800 […]
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: ...
Maxim Group started coverage on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $4.00 price objective on the stock. Context Therapeutics Trading Down 2.9 % Shares of CNTX stock opened at $1.02 on Monday. […]
Maxim Group started coverage on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report issued on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $4.00 price target on the stock. Context Therapeutics Stock Performance Context Therapeutics stock opened at $1.02 on Monday. The firm has a market cap of […]